Tislelizumab with chemoradiotherapy for stage IIIC2 cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- Your cervical cancer was confirmed under a microscope as one of these types: squamous, adenocarcinoma, or adenosquamous
- You have stage IIIC2 cervical cancer (2018 FIGO stage) and it has not spread to distant sites (no metastasis)
- You have at least one measurable tumor area that can be tracked on scans
- Your health status is good enough for treatment (ECOG 0–1) and you have enough blood and organ function
- You have not had certain cancer medicines or immune-related treatments before, and you do not have major immune or uncontrolled health problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial is testing a new immunotherapy drug (adebrelimab) given along with standard chemoradiation for advanced cervical cancer. The goal is to see if adding this drug improves treatment effectiveness.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.